ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in clinical trials. Here, we discuss the potential for e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Jette, Nicholas R., Kumar, Mehul, Radhamani, Suraj, Arthur, Greydon, Goutam, Siddhartha, Yip, Steven, Kolinsky, Michael, Williams, Gareth J., Bose, Pinaki, Lees-Miller, Susan P.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140103/
https://ncbi.nlm.nih.gov/pubmed/32183301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030687
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados